22 Jun Substantial Number of Deaths in Heart Failure Patients Can Be Reduced with ANRI Therapy

Posted at 19:23h in Author Interviews, Heart Disease, JAMA, Pharmacology, UCLA by

MedicalResearch.com Interview with:

Gregg C. Fonarow, MD, FACC, FAHA Eliot Corday Professor of Cardiovascular Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Chief of Clinical Cardiology, UCLA Division of Cardiology Co-Director, UCLA Preventative Cardiology Program David Geffen School of Medicine at UCLA Los Angeles, CA, 90095-1679

Dr. Gregg Fonarow

Gregg C. Fonarow, MD, FACC, FAHA
Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Chief of Clinical Cardiology, UCLA Division of Cardiology
Co-Director, UCLA Preventative Cardiology Program
David Geffen School of Medicine at UCLA
Los Angeles, CA, 90095-1679

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Fonarow: Angiotensin receptor neprilysin inhibitors (ARNI) have been demonstrated to reduce mortality in patients with heart failure with reduced ejection fraction. However, to date, the population level impact of optimal implementation of this therapy in the United States has not been evaluated.

This new analysis estimates that as many 28,484 deaths in heart failure with reduced ejection fraction patients annually could be prevented or postponed with optimal use of angiotensin receptor neprilysin inhibitors (with sensitivity analyses demonstrating a range of 18,230 to 41,017).

MedicalResearch.com: What should readers take away from your report?

Dr. Fonarow: A substantial number of deaths could be prevented each year with optimal implementation of ANRI therapy for eligible heart failure patients.

These findings support efforts to ensure timely implementation of evidence and guidelines into clinical practice as this will have a material impact on the health and outcomes among patients with heart failure.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Dr. Fonarow: Further studies regarding the real world effectiveness of this therapy in types of patients not well represented in the PARADIGM-HF trial which established the benefits of ARNI therapy over ACE inhibitors in heart failure.

MedicalResearch.com: Is there anything else you would like to add?

Dr. Fonarow: ARNI therapy has also been demonstrated to reduce hospitalizations for heart failure.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Gaziano TA, Fonarow GC, Claggett B, et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. Published online June 22, 2016. doi:10.1001/jamacardio.2016.1747.

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

[wysija_form id=”5″]

Last Updated on June 22, 2016 by Marie Benz MD FAAD

344
Tags: